SCHEMBL2806937

SCHEMBL2806937

COCCCOc1cc(C=O)cc(Cl)c1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.48
L3MBTL1 Q9Y468 6/20 0.48
CYP1A2 P05177 5/20 0.48
CYP2C19 P33261 4/20 0.48
CYP3A4 P08684 2/20 0.48
PKM P14618 1/20 0.48
FDPS P14324 1/20 0.45
MAPT P10636 10/20 0.44
HPGD P15428 6/20 0.44
KMT2A Q03164 2/20 0.44
MAPK1 P28482 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
POLB P06746 2/20 0.44
MEN1 O00255 1/20 0.44
ALOX12 P18054 1/20 0.44
RECQL P46063 1/20 0.44
CYP2C9 P11712 4/20 0.43
CYP2D6 P10635 1/20 0.43
LMNA P02545 3/20 0.41
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2809278 0.84 FDPS (0.46) ALDH1A1L3MBTL1CYP1A2CYP2C19FDPS
SCHEMBL2808779 0.82 ALDH1A1 (0.52) ALDH1A1CYP1A2CYP2C19FDPSMAPT
SCHEMBL2810172 0.82 FDPS (0.45) ALDH1A1L3MBTL1CYP1A2CYP2C19FDPS
SCHEMBL524215 0.81 KMT2A (0.55) ALDH1A1L3MBTL1CYP1A2CYP2C19CYP3A4
SCHEMBL20482174 0.79 LMNA (0.59) ALDH1A1L3MBTL1CYP1A2CYP2C19FDPS
SCHEMBL7951853 0.78 ALDH1A1 (0.50) ALDH1A1L3MBTL1CYP1A2CYP2C19CYP3A4
SCHEMBL27339812 0.78 ALDH1A1 (0.44) ALDH1A1L3MBTL1CYP1A2CYP2C19FDPS
SCHEMBL2391793 0.77 ALDH1A1 (0.46) ALDH1A1L3MBTL1CYP1A2CYP2C19CYP3A4
SCHEMBL4007449 0.77 ALDH1A1 (0.51) ALDH1A1L3MBTL1CYP1A2CYP2C19CYP3A4
SCHEMBL22301646 0.76 FDPS (0.51) ALDH1A1L3MBTL1FDPSMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
EP-2168952-A1 MORPHOLINE DERIVATIVE Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 ALDH1A1 2202/4885L3MBTL1 4737/4885CYP1A2 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.